𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease

✍ Scribed by A. Moser; F. Siebecker; P. Vieregge; P. Jaskowski; D. Kömpf

Publisher
Springer
Year
1996
Tongue
English
Weight
808 KB
Volume
103
Category
Article
ISSN
1435-1463

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Visual object recognition and attention
Visual object recognition and attention in Parkinson's disease patients with visual hallucinations
✍ Anne Marthe Meppelink; Janneke Koerts; Maarten Borg; Klaus Leonard Leenders; Teu 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 240 KB 👁 1 views

## Abstract Visual hallucinations (VH) are common in Parkinson's disease (PD) and are hypothesized to be due to impaired visual perception and attention deficits. We investigated whether PD patients with VH showed attention deficits, a more specific impairment of higher order visual perception, or

Neuropsychological deficits in Parkinson
Neuropsychological deficits in Parkinson's disease patients with visual hallucinations
✍ Blanca Ramírez-Ruiz; Carme Junqué; María-José Martí; Francesc Valldeoriola; Edua 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

## Abstract Recent neuropathological and neuroimaging studies suggest the involvement of several temporal regions in Parkinson's disease (PD) patients with visual hallucinations (VH). We examined 24 nondemented PD patients with VH, 21 PD patients without VH, and 21 healthy controls using a battery

Simultaneous MAO-B and COMT inhibition i
Simultaneous MAO-B and COMT inhibition in L-dopa-treated patients with parkinson's disease
✍ Dr. Jukka Lyytinen; Seppo Kaakkola; Sirpa Ahtila; Päivi Tuomainen; Heikki Terävä 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 801 KB

## Abstract The effect of selegiline (L‐deprenyl) on plasma catecholamines, clinical response, and drug tolerability was studied in 13 patients with Parkinson's disease (PD) treated with L‐Dopa/benserazide and entacapone, a peripheral catechol‐__O__‐methyltransferase (COMT) inhibitor, in a placebo‐

Visual hallucinations as REM sleep behav
Visual hallucinations as REM sleep behavior disorders in patients with Parkinson's disease
✍ Takashi Nomura; Yuichi Inoue; Hidetaka Mitani; Ryuzo Kawahara; Masahiro Miyake; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 443 KB

## Abstract To clarify whether visual hallucinations in patients with Parkinson's disease (PD) are related to rapid eye movement (REM) sleep, nocturnal polysomnographic variables were compared between a group with hallucinations (hallucinators, n = 14) and a group without hallucinations (nonhalluci

Effects of rivastigmine in patients with
Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease
✍ David Burn; Murat Emre; Ian McKeith; Peter Paul De Deyn; Dag Aarsland; Chuanchie 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 190 KB 👁 1 views

## Abstract We aimed to determine prospectively whether rivastigmine, an inhibitor of acetylcholinesterase and butyrylcholinesterase, provided benefits in patients with and without visual hallucinations in a population with dementia associated with Parkinson's disease (PDD). This was a 24‐week doub